Cost-effectiveness analysis of ixabepilone use in monotherapy in patients with locally advanced and metastatic breast cancer resistant to treatment with anthracyclines, taxanes and capecitabin
Background. Nowadays there are no any standards of treatment for patients with locally advanced and metastatic breast cancer resistant to treatment with anthracyclines, taxanes and capecitabin. Ixabepilone has proved successful as a single agent for treatment of these patients. Methods. Eribulin was...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IP Habib O.N.
2018-03-01
|
| Series: | Современная онкология |
| Subjects: | |
| Online Access: | https://modernonco.orscience.ru/1815-1434/article/viewFile/27173/pdf |
| _version_ | 1818536637936697344 |
|---|---|
| author | A S Kolbin A A Mosikyan Y E Balykina M A Proskurin |
| author_facet | A S Kolbin A A Mosikyan Y E Balykina M A Proskurin |
| author_sort | A S Kolbin |
| collection | DOAJ |
| description | Background. Nowadays there are no any standards of treatment for patients with locally advanced and metastatic breast cancer resistant to treatment with anthracyclines, taxanes and capecitabin. Ixabepilone has proved successful as a single agent for treatment of these patients. Methods. Eribulin was chosen as an alternative strategy. Efficacy criteria were overall and progression-free survival. Cost-effectiveness analysis is performed on the basis of published data and Markov modeling for 1.5 year time horizon. Results. Total expenditures for ixabepilone strategy were 18.2% less than those for eribulin treatment. Administration of ixabepilone instead of eribulin will allow treating additionally up to 222 patients per year. Price elasticity analysis revealed that total expenditures on ixabepilone will be 20% less than on eribulin treatment at a price of ixabepilone equal to 63 000 rubles per 45 mg vial and 21 691.23 rubles per 15 mg vial of ixabepilone. Conclusion. Ixabepilone as a single agent appeared to be economically reasonable as compared to eribulin in case of ineffective pretreatment with taxanes, anthracyclines and capecitabine. |
| first_indexed | 2024-12-11T18:40:31Z |
| format | Article |
| id | doaj.art-1d07e825b849420aa935b896ce105490 |
| institution | Directory Open Access Journal |
| issn | 1815-1434 1815-1442 |
| language | Russian |
| last_indexed | 2024-12-11T18:40:31Z |
| publishDate | 2018-03-01 |
| publisher | IP Habib O.N. |
| record_format | Article |
| series | Современная онкология |
| spelling | doaj.art-1d07e825b849420aa935b896ce1054902022-12-22T00:54:37ZrusIP Habib O.N.Современная онкология1815-14341815-14422018-03-01201646924393Cost-effectiveness analysis of ixabepilone use in monotherapy in patients with locally advanced and metastatic breast cancer resistant to treatment with anthracyclines, taxanes and capecitabinA S Kolbin0A A Mosikyan1Y E Balykina2M A Proskurin3I.P.Pavlov First Saint Petersburg State Medical University of the Ministry of Health of the Russian Federation; Saint Petersburg State UniversityV.A.Almazov National Medical Research CenterSaint Petersburg State UniversitySaint Petersburg State UniversityBackground. Nowadays there are no any standards of treatment for patients with locally advanced and metastatic breast cancer resistant to treatment with anthracyclines, taxanes and capecitabin. Ixabepilone has proved successful as a single agent for treatment of these patients. Methods. Eribulin was chosen as an alternative strategy. Efficacy criteria were overall and progression-free survival. Cost-effectiveness analysis is performed on the basis of published data and Markov modeling for 1.5 year time horizon. Results. Total expenditures for ixabepilone strategy were 18.2% less than those for eribulin treatment. Administration of ixabepilone instead of eribulin will allow treating additionally up to 222 patients per year. Price elasticity analysis revealed that total expenditures on ixabepilone will be 20% less than on eribulin treatment at a price of ixabepilone equal to 63 000 rubles per 45 mg vial and 21 691.23 rubles per 15 mg vial of ixabepilone. Conclusion. Ixabepilone as a single agent appeared to be economically reasonable as compared to eribulin in case of ineffective pretreatment with taxanes, anthracyclines and capecitabine.https://modernonco.orscience.ru/1815-1434/article/viewFile/27173/pdfpharmacoeconomicsclinical and economic analysisixabepilonemetastatic breast canceranthracyclinestaxanescapecitabineresistantsingle agent |
| spellingShingle | A S Kolbin A A Mosikyan Y E Balykina M A Proskurin Cost-effectiveness analysis of ixabepilone use in monotherapy in patients with locally advanced and metastatic breast cancer resistant to treatment with anthracyclines, taxanes and capecitabin Современная онкология pharmacoeconomics clinical and economic analysis ixabepilone metastatic breast cancer anthracyclines taxanes capecitabine resistant single agent |
| title | Cost-effectiveness analysis of ixabepilone use in monotherapy in patients with locally advanced and metastatic breast cancer resistant to treatment with anthracyclines, taxanes and capecitabin |
| title_full | Cost-effectiveness analysis of ixabepilone use in monotherapy in patients with locally advanced and metastatic breast cancer resistant to treatment with anthracyclines, taxanes and capecitabin |
| title_fullStr | Cost-effectiveness analysis of ixabepilone use in monotherapy in patients with locally advanced and metastatic breast cancer resistant to treatment with anthracyclines, taxanes and capecitabin |
| title_full_unstemmed | Cost-effectiveness analysis of ixabepilone use in monotherapy in patients with locally advanced and metastatic breast cancer resistant to treatment with anthracyclines, taxanes and capecitabin |
| title_short | Cost-effectiveness analysis of ixabepilone use in monotherapy in patients with locally advanced and metastatic breast cancer resistant to treatment with anthracyclines, taxanes and capecitabin |
| title_sort | cost effectiveness analysis of ixabepilone use in monotherapy in patients with locally advanced and metastatic breast cancer resistant to treatment with anthracyclines taxanes and capecitabin |
| topic | pharmacoeconomics clinical and economic analysis ixabepilone metastatic breast cancer anthracyclines taxanes capecitabine resistant single agent |
| url | https://modernonco.orscience.ru/1815-1434/article/viewFile/27173/pdf |
| work_keys_str_mv | AT askolbin costeffectivenessanalysisofixabepiloneuseinmonotherapyinpatientswithlocallyadvancedandmetastaticbreastcancerresistanttotreatmentwithanthracyclinestaxanesandcapecitabin AT aamosikyan costeffectivenessanalysisofixabepiloneuseinmonotherapyinpatientswithlocallyadvancedandmetastaticbreastcancerresistanttotreatmentwithanthracyclinestaxanesandcapecitabin AT yebalykina costeffectivenessanalysisofixabepiloneuseinmonotherapyinpatientswithlocallyadvancedandmetastaticbreastcancerresistanttotreatmentwithanthracyclinestaxanesandcapecitabin AT maproskurin costeffectivenessanalysisofixabepiloneuseinmonotherapyinpatientswithlocallyadvancedandmetastaticbreastcancerresistanttotreatmentwithanthracyclinestaxanesandcapecitabin |